Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cullinan Management (CGEM – Research Report), Ionis Pharmaceuticals (IONS – Research Report) and 89bio (ETNB – Research Report).
Cullinan Management (CGEM)
BTIG analyst Kaveri Pohlman maintained a Buy rating on Cullinan Management today and set a price target of $30.00. The company’s shares closed last Thursday at $23.81.
According to TipRanks.com, Pohlman is a 1-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cullinan Management with a $33.83 average price target, implying a 26.3% upside from current levels. In a report issued on May 1, Stifel Nicolaus also initiated coverage with a Buy rating on the stock with a $40.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Ionis Pharmaceuticals (IONS)
In a report released today, Jessica Fye from J.P. Morgan maintained a Hold rating on Ionis Pharmaceuticals. The company’s shares closed last Thursday at $37.62, close to its 52-week low of $34.99.
According to TipRanks.com, Fye is a 4-star analyst with an average return of
Ionis Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $58.25, representing a 49.4% upside. In a report issued on May 10, Barclays also assigned a Hold rating to the stock with a $45.00 price target.
89bio (ETNB)
In a report released today, Justin Zelin from BTIG maintained a Buy rating on 89bio, with a price target of $37.00. The company’s shares closed last Thursday at $8.97, close to its 52-week low of $6.58.
According to TipRanks.com, Zelin is a 5-star analyst with an average return of
Currently, the analyst consensus on 89bio is a Moderate Buy with an average price target of $28.00, implying a 202.7% upside from current levels. In a report issued on May 10, H.C. Wainwright also maintained a Buy rating on the stock with a $29.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CGEM:
- Cullinan Management Welcomes David Meek to Board of Directors
- Cullinan Therapeutics reports Q1 EPS (86c), consensus (99c)
- Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- Investor Sentiment Swings in Favor of Cullinan Therapeutics (NASDAQ:CGEM)
- Starbucks downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
